Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subdissociative Dose Ketamine for Acute Pain in Chronic Pain
NCT02920528Phase 3Completed
- Sponsor
- The Lundquist Institute
- Start
- May 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in chronic pain (3 arms), sponsored by The Lundquist Institute. Primary endpoint: Percentage of Subjects Who Achieved Significant Pain Relief at 60 months. Started May 2017; status: completed.
02
Drugs
ketamine
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT02920528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920528.